



Deal Sheet Summary – Promising combination with PD-1 inhibitor

Leap Therapeutics and BeiGene



Responsibility

- Responsible for conducting POC studies
- Retains Development & Commercialization rights in the rest of the world
- Manufacturing and Supply

Collaboration Focus

BeiGene granted an option to clinically develop and commercialize DKN-01 antibody in Asia (excluding Japan), Australia and New Zealand

Option Right

BeiGene option to an exclusive license to DKN-01 following initial proof-of-concept studies

Financial Terms

\$3M Upfront payment
\$129M Option exercise, Development, Regulatory & Commercial milestones

Total Deal Value:

\$132M plus Royalty payments

\$5M Equity Investment into Leap by BeiGene

Responsibility

- Clinical Development & Commercialization rights in Asia (excluding Japan) Australia, and New Zealand